Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320632 · ClinicalTrials.gov registry record · Phase 4
Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression
A Phase 4 study, sponsored by Harvard Medical School (HMS and HSDM).
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT00320632 is a Phase 4 study that has completed, run by Harvard Medical School (HMS and HSDM). The registered enrollment target is 43 participants.
The verdict
NCT00320632, a Phase 4 study, has completed, sponsored by Harvard Medical School (HMS and HSDM).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of desipramine in improving cellular signaling, and thereby decreasing symptoms of depression in people with major depressive disorder (MDD).
Interventions
- DRUG Desipramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 1990-08 |
| Est. Completion | 1993-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00320632
The ClinicalTrials.gov registry entry for NCT00320632 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harvard Medical School (HMS and HSDM), which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Desipramine is the first listed.
NCT00320632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00320632 about?
NCT00320632 is a clinical study titled "Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression". This study will determine the effectiveness of desipramine in improving cellular signaling, and thereby decreasing symptoms of depression in people with major depressive disorder (MDD).
What is the current status of trial NCT00320632?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 1990-08. Estimated completion is 1993-07.
What interventions are being tested in trial NCT00320632?
The interventions under investigation include: Desipramine (DRUG).
Who is sponsoring clinical trial NCT00320632?
This trial is sponsored by Harvard Medical School (HMS and HSDM), which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.